Business
Physiomics Awarded Two New Contracts
Physiomics plc has secured two new modelling and simulation contracts totaling £29,750, with one contract valued at £13,600 extending an existing relationship with a UK biotech firm using the Virtual Tumour Platform for oncology drug dosing, and another new contract worth £16,150 with a UK biotech client focused on renal disease therapies, which may lead to further projects. Disclaimer*
About this update from Physiomics Plc
[{"type":"text","content":"\n\n4 December 2025\n \nPhysiomics plc\n(\"Physiomics\" or the \"Company\")\n \nPhysiomics Awarded Two New Contracts\n \nPhysiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce the award of two new modelling and simulation contracts with the total value of £29,750.\n \nContract Award 1:\nPhysiomics has secured a contract with a UK-based biotech firm specialising in AI-powered drug development. Building on an earlier projects announced on 25 June 2025 and 6 August 2025, this new agreement is worth £13,600 and involves using Physiomics' unique Virtual Tumour Platform to guide dosing decisions for the client's leading oncology drug. The project is scheduled to complete within the next month.\n \nContract Award 2:\nPhysiomics has secured a contract in collaboration with a partner to support a UK-based biotech client in the development of renal disease therapies. Valued at £16,150, this project focuses on establishing a modelling and simulation strategy to advance the client's drug development efforts.\nWhile future opportunities cannot be guaranteed, the Company anticipates that this initial engagement may lead to larger projects involving further execution of modelling and simulation initiatives for the client. Completion of this project is expected within the next month.\n \nDr Peter Sargent, CEO of Physiomics, commented:\n\"We are thrilled to have secured these two contracts. Extending our agreement with an existing client (Contract Award 1) demonstrates the value we deliver and our strong rate of repeat business. Additionally, winning a contract with a new client (Contract Award 2) highlights both our commitment to continue diversifying our client base as well as expand into therapeutic areas beyond oncology\".\n \nFor more information about Physiomics and its services, please visit www.physiomics.co.uk.\n \nEnquiries:\n \nPhysiomics plc\nDr Peter Sargent, CEO\n+44 (0)1235 841575\n \nHybridan LLP (Broker)\nClaire Louise Noyce\n+44 (0) 203 764 2341\n \nStrand Hanson Ltd (NOMAD)\nJames Dance & James Bellman\n+44 (0)20 7409 3494\n \n \nNotes to Editor\n \nAbout Physiomics\n \nPhysiomics plc combines ...